BREAKING:

This episode explores iX Biopharma’s strategic pivot toward high-growth wellness and the U.S. compounding pharmacy market. We delve into their proprietary sublingual technology, which offers superior absorption and immediate commercial potential. Learn how a disciplined focus on longevity and clinical-ready assets is transforming their financial landscape.

• Uncover the explosive momentum within the longevity segment and the flagship supplement captivating global consumers

• Discover a capital-light pathway for rapid entry into the American healthcare market

• Get updates on a breakthrough pain-management platform attracting major government interest

WATCH THE EXPLAINER VIDEO BELOW:

LISTEN TO THE PODCAST BELOW:

BREAKING:

iX Biopharma LTD achieved robust financial performance with significant revenue and gross profit growth, alongside reduced adjusted EBITDA losses. The Group is strategically scaling its wellness business and accelerating its pharmaceutical pipeline's market entry, leveraging unique sublingual technologies.

• Discover how proprietary sublingual technologies are revolutionising drug delivery and market potential

• Explore a key wellness product's strategic expansion into a dynamic longevity market

• Learn about the accelerated commercialisation of pharmaceutical assets through targeted partnerships

LISTEN TO THE PODCAST BELOW:

There will be an AGM on

Event dates:

For more information, click here: IX BIOPHARMA LTD. 2023 AGM